Drs. Anil Kishen and Annie Shrestha spoke with Dr. Chiraz Guessaier about the UNO-Gel, a new product that was developed in Dr. Kishen’s lab at the Faculty of Dentistry at the University of Toronto and which counters dentin hypersensitivity.
Highlights
- Dentin sensitivity, an age-old problem affecting an estimated 98% of the population at some point in their lives.
- Launching the product is Germiphene Corporation, which has partnered with start-up company Oral Antibacterials Inc., founded by Professor Anil Kishen and graduate student Dr. Annie Shrestha, to develop the product.
- Leveraging their strength in endodontics and nanoparticle technology, the team developed BioSchell, a naturally-derived bioactive nanoparticle polymer for application in the gel product. In conjunction with the gel, these particles form a rapid, protective biocompatible layer overtop the dentin, effectively ending the hypersensitive reaction.
- George Botos, VP of Business Development at Germiphene, agrees. “UNO is the most exciting product launched by Germiphene Corporation in a long time,” said Botos in a statement. He added, “we really believe that the technology commercialized by Oral Antibacterials [Inc.] will create a new industry standard in terms of hypersensitivity treatment in the dental office.”
- The commercialization of UNO gel was supported in part by the University of Toronto’s Impact Centre.